We Analyzed the Future Direction of Clovis Oncology Inc. (CLVS), Here is What We Found – News Heater

We Analyzed the Future Direction of Clovis Oncology Inc. (CLVS), Here is What We Found

Share on facebook
Share on twitter
Share on linkedin
Share on whatsapp

Clovis Oncology Inc. (NASDAQ:CLVS) went up by 17.15% from its latest closing price compared to the recent 1-year high of $11.63. The company’s stock price has collected 18.48% of gains in the last five trading sessions. Press Release reported on 02/04/21 that Clovis Oncology to Highlight Data at ASCO 2021 Genitourinary Cancers Symposium Virtual Meeting

Get the hottest stocks to trade every day before the market opens 100% free. Click here now.

Is It Worth Investing in Clovis Oncology Inc. (NASDAQ :CLVS) Right Now?

Plus, the 36-month beta value for CLVS is at 1.71. Opinions of the stock are interesting as 1 analysts out of 7 who provided ratings for Clovis Oncology Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 3 rated it as “hold,” and 2 as “sell.”


5 Stocks Under $10 That Are Poised to Take Off

Investing in stocks under $10 could significantly increase the returns on your portfolio, especially if you pick the right stocks! Within this report you will find 5 top stocks that offer investors huge upside potential and the best bang for their buck.

Add them to your watchlist before they take off!

Get the Top 5 Stocks Now!

Sponsored



The average price from analysts is $7.00, which is -$2.03 below the current price. CLVS currently public float of 86.48M and currently shorts hold a 41.76% ratio of that float. Today, the average trading volume of CLVS was 6.60M shares.

CLVS’s Market Performance

CLVS stocks went up by 18.48% for the week, with a monthly jump of 94.59% and a quarterly performance of 65.08%, while its annual performance rate touched -7.33%. The volatility ratio for the week stands at 10.01% while the volatility levels for the past 30 days are set at 11.74% for Clovis Oncology Inc.. The simple moving average for the period of the last 20 days is 35.99% for CLVS stocks with a simple moving average of 51.59% for the last 200 days.

Analysts’ Opinion of CLVS

Many brokerage firms have already submitted their reports for CLVS stocks, with H.C. Wainwright repeating the rating for CLVS by listing it as a “Buy.” The predicted price for CLVS in the upcoming period, according to H.C. Wainwright is $33 based on the research report published on May 18th of the previous year 2020.

SVB Leerink, on the other hand, stated in their research note that they expect to see CLVS reach a price target of $5. The rating they have provided for CLVS stocks is “Underperform” according to the report published on April 27th, 2020.

BofA/Merrill gave a rating of “Underperform” to CLVS, setting the target price at $6 in the report published on April 09th of the previous year.

CLVS Trading at 64.53% from the 50-Day Moving Average

After a stumble in the market that brought CLVS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -19.52% of loss for the given period.

Volatility was left at 11.74%, however, over the last 30 days, the volatility rate increased by 10.01%, as shares surge +87.95% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +123.92% upper at present.

During the last 5 trading sessions, CLVS rose by +18.48%, which changed the moving average for the period of 200-days by +2.07% in comparison to the 20-day moving average, which settled at $7.10. In addition, Clovis Oncology Inc. saw 95.00% in overturn over a single year, with a tendency to cut further gains.

Insider Trading

Reports are indicating that there were more than several insider trading activities at CLVS starting from IVERS-READ GILLIAN C, who sale 10,990 shares at the price of $7.97 back on Feb 02. After this action, IVERS-READ GILLIAN C now owns 234,877 shares of Clovis Oncology Inc., valued at $87,590 using the latest closing price.

Rolfe Lindsey, the See Remarks of Clovis Oncology Inc., sale 11,813 shares at $7.97 during a trade that took place back on Feb 02, which means that Rolfe Lindsey is holding 60,034 shares at $94,150 based on the most recent closing price.

Stock Fundamentals for CLVS

Current profitability levels for the company are sitting at:

  • -256.85 for the present operating margin
  • +75.75 for the gross margin

The net margin for Clovis Oncology Inc. stands at -280.01. The total capital return value is set at -58.15, while invested capital returns managed to touch -63.72. Equity return is now at value 263.20, with -59.30 for asset returns.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now.

When we switch over and look at the enterprise to sales, we see a ratio of 6.85, with the company’s debt to enterprise value settled at 0.73. The receivables turnover for the company is 5.74 and the total asset turnover is 0.19. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.75.

Sign up for our FREE Newsletter and get:

Leave a Comment

Your email address will not be published. Required fields are marked *

Sign up for our FREE Newsletter and get:

Get The Best Stocks To Trade Every Day!...100% Free

We do not sell or share your information with anyone.

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

We do not sell or share your information with anyone.

Get Best Morning Financial Newsletter... 100% Free

Best stocks ideas

Analysts’ Upgrades & Downgrades

Important Earnings

Insider Watchlist

We do not sell or share your information with anyone.